<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03441581</url>
  </required_header>
  <id_info>
    <org_study_id>3030-401-002</org_study_id>
    <nct_id>NCT03441581</nct_id>
  </id_info>
  <brief_title>Eluxadoline Bile Acid Malabsorption (BAM) Study</brief_title>
  <official_title>3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the possibility of a differential effect of eluxadoline on altered&#xD;
      bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) participants with and&#xD;
      without evidence of Bile Acid Malabsorption (BAM).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2018</start_date>
  <completion_date type="Actual">April 28, 2020</completion_date>
  <primary_completion_date type="Actual">April 28, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score Over 4 Weeks of Treatment Period</measure>
    <time_frame>Baseline (Day 1) to Week 4</time_frame>
    <description>Stool consistency was assessed using the BSFS where: 1=Separate hard lumps like nuts to 7=Watery. The score was recorded by the participant in an electronic diary (e-diary). The score for each day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline (Day 1) to Week 4</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is an AE that occurs or worsens after receiving investigational study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced Potentially Clinically Significant Change in Laboratory Tests</measure>
    <time_frame>Baseline (Day 1) to Week 4</time_frame>
    <description>Laboratory tests included tests of Clinical Chemistry, Hematology, and Urinalysis. The investigator determined if the result was potentially clinically significant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced Potentially Clinically Significant Change in Vital Signs</measure>
    <time_frame>Baseline (Day 1) to Week 4</time_frame>
    <description>Vital signs assessments included: pulse, respiratory rate, and blood pressure (systolic and diastolic). The investigator determined if the result was potentially clinically significant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced Clinically Significant Change From Baseline in General Physical Condition as Measured Through General Physical Exam</measure>
    <time_frame>Baseline (Day 1) to Week 4</time_frame>
    <description>General Physical Examination consisted of a full review of body systems excluding pelvic and rectal exams. The investigator determined if the result was clinically significant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 4-week Average of Daily Bowel Movement Frequency During the Treatment Period</measure>
    <time_frame>Baseline (Day 1) to Week 4</time_frame>
    <description>Bowel movements were recorded by the participant in an electronic diary (e-diary). The number of bowel movements per day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 4-week Average of Daily Worst Abdominal Pain Scores During the Treatment Period</measure>
    <time_frame>Baseline (Day 1) to Week 4</time_frame>
    <description>The participant recorded their worst abdominal pain score in the past 24 hours each day in an e-diary where: 0=no pain to 10=worst imaginable pain. The score each day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 4-week Average of Daily Bloating Scores During the Treatment Period</measure>
    <time_frame>Baseline (Day 1) to Week 4</time_frame>
    <description>The participant recorded their bloating score in the past 24 hours each day in an e-diary where: 0=no bloating to 10=worst imaginable bloating. The score each day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 4-week Average Number of Daily Urgent Bowel Movements During the Treatment Period</measure>
    <time_frame>Baseline (Day 1) to Week 4</time_frame>
    <description>The participant recorded the number of urgent bowel movements in the past 24 hours each day in an e-diary. The number of urgent bowel movements per day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Fecal Incontinence During the Treatment Period</measure>
    <time_frame>Baseline (Day 1) to Week 4</time_frame>
    <description>The participant recorded the number of fecal incontinences in the past 24 hours each day in an e-diary. Fecal incontinence is the inability to control the passage of gas or stools. The number of fecal incontinences per day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Irritable Bowel Syndrome Quality of Life (IBS-QOL) Total Score at the End of the Treatment Period</measure>
    <time_frame>Baseline (Day1) to End of Treatment (Up to Week 4)</time_frame>
    <description>IBS-QOL is composed of 34 items about how the symptoms of IBS are impacting the participant's life scored on a 1 to 5 scale, where lower item scores indicate greater quality of life. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0 to 100-point scale (0=worst; 100=better) for ease of interpretation. A positive change from Baseline indicates improved quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Serum 7α-hydroxy-4-cholesten-3-one (7αC4) Levels at the End of the Treatment Period</measure>
    <time_frame>Baseline (Day 1) to End of Treatment (Up to Week 4)</time_frame>
    <description>Participants fasted for at least 8 hours prior to the test. Fasting serum 7αC4 level was measured at Baseline and End of Treatment to determine whether any changes occurred following treatment with eluxadoline. The negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Concentration for Eluxadoline</measure>
    <time_frame>Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin: Minimum Concentration for Eluxadoline</measure>
    <time_frame>Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC: Area Under the Concentration-time Curve During the Dosing Interval for Eluxadoline</measure>
    <time_frame>Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Cmax for Eluxadoline</measure>
    <time_frame>Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2: Half-Life for Eluxadoline</measure>
    <time_frame>Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Apparent Total Clearance of the Drug From Plasma After Oral Administration for Eluxadoline</measure>
    <time_frame>Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vc/F: Apparent Volume of Distribution for Eluxadoline</measure>
    <time_frame>Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Irritable Bowel Syndrome With Diarrhea</condition>
  <arm_group>
    <arm_group_label>Eluxadoline 100 mg with BAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eluxadoline 100 mg without BAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eluxadoline</intervention_name>
    <description>Eluxadoline 100 mg oral tablets BID with food.</description>
    <arm_group_label>Eluxadoline 100 mg with BAM</arm_group_label>
    <arm_group_label>Eluxadoline 100 mg without BAM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult men or women aged 18 to 75 years inclusive with a diagnosis of IBS-D per Rome IV&#xD;
             criteria.&#xD;
&#xD;
          -  Participants with evidence of BAM must have a fasting serum&#xD;
             7a-hydroxy-4-cholesten-3-one (7αC4) level ≥ 52.5 ng/mL or total fecal bile acid (BA) &gt;&#xD;
             2337 micromoles/48 hours (positive result) at screening or within 1 calendar year&#xD;
             prior to screening.&#xD;
&#xD;
          -  Participants without BAM must have a fasting serum 7αC4 level ≤ 47.1 ng/mL or total&#xD;
             fecal BA &lt; 2200 micromoles/48 hours (negative result) at screening or within 1&#xD;
             calendar year prior to screening.&#xD;
&#xD;
          -  Has an average daily Bristol Stool Form Scale (BSFS) score ≥ 5.0 or ≥ 25% of diary&#xD;
             entry days with a BSFS score of 6 or 7 during the 14 days prior to Day 1.&#xD;
&#xD;
          -  Women of childbearing potential must use hormonal or double barrier contraception or&#xD;
             maintain a monogamous relationship with a vasectomized male partner from the date of&#xD;
             informed consent until 24 hours after final dose of study drug.&#xD;
&#xD;
          -  Completed the electronic diary (eDiary) on ≥ 10 of the 14 days prior to Day 1.&#xD;
&#xD;
          -  Has not used loperamide rescue medication on &gt; 3 of the 14 days prior to Day 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a diagnosis of IBS with a subtype of irritable bowel syndrome with constipation&#xD;
             (IBS-C), mixed IBS, or unsubtyped IBS per Rome IV criteria.&#xD;
&#xD;
          -  Does not have a gallbladder.&#xD;
&#xD;
          -  Has known or suspected biliary duct obstruction, or sphincter of Oddi disease or&#xD;
             dysfunction. (Participants with a history of gallstones may be enrolled).&#xD;
&#xD;
          -  Has a history of alcoholism, alcohol abuse or alcohol addiction, or drinks more than 3&#xD;
             alcoholic beverages per day.&#xD;
&#xD;
          -  Has a history of pancreatitis; structural diseases of the pancreas, including known or&#xD;
             suspected pancreatic duct obstruction.&#xD;
&#xD;
          -  Has a history of mild, moderate, or severe hepatic impairment according to Child-Pugh&#xD;
             classification. History or current diagnosis of inflammatory or immune-mediated&#xD;
             gastrointestinal (GI) disorders.&#xD;
&#xD;
          -  Has Celiac disease or a positive serological test for celiac disease.&#xD;
&#xD;
          -  Has known lactose or fructose intolerance associated with diarrhea, abdominal pain or&#xD;
             discomfort, that could confound assessments in the study.&#xD;
&#xD;
          -  Women who are currently pregnant or nursing, or plan to become pregnant or nurse&#xD;
             during the study.&#xD;
&#xD;
          -  Has known allergies or hypersensitivity to opioids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Muslin</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <results_first_submitted>April 28, 2021</results_first_submitted>
  <results_first_submitted_qc>April 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2021</results_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBS-D</keyword>
  <keyword>BAM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Malabsorption Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eluxadoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03441581/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03441581/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Eluxadoline 100 mg With BAM</title>
          <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Eluxadoline 100 mg Without BAM</title>
          <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population included of all participants who received ≥ 1 dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Eluxadoline 100 mg With BAM</title>
          <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Eluxadoline 100 mg Without BAM</title>
          <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.6" spread="6.07"/>
                    <measurement group_id="B2" value="40.2" spread="13.72"/>
                    <measurement group_id="B3" value="40.9" spread="10.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score Over 4 Weeks of Treatment Period</title>
        <description>Stool consistency was assessed using the BSFS where: 1=Separate hard lumps like nuts to 7=Watery. The score was recorded by the participant in an electronic diary (e-diary). The score for each day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1) to Week 4</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population included of all participants in Enrolled Population with ≥ 1 postbaseline assessment for BSFS.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score Over 4 Weeks of Treatment Period</title>
          <description>Stool consistency was assessed using the BSFS where: 1=Separate hard lumps like nuts to 7=Watery. The score was recorded by the participant in an electronic diary (e-diary). The score for each day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
          <population>Modified Intent-to-Treat (mITT) Population included of all participants in Enrolled Population with ≥ 1 postbaseline assessment for BSFS.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.89" spread="0.639"/>
                    <measurement group_id="O2" value="5.34" spread="0.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="0.914"/>
                    <measurement group_id="O2" value="-1.09" spread="0.902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is an AE that occurs or worsens after receiving investigational study drug.</description>
        <time_frame>Baseline (Day 1) to Week 4</time_frame>
        <population>Safety Population included of all participants who received ≥ 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is an AE that occurs or worsens after receiving investigational study drug.</description>
          <population>Safety Population included of all participants who received ≥ 1 dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7"/>
                    <measurement group_id="O2" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced Potentially Clinically Significant Change in Laboratory Tests</title>
        <description>Laboratory tests included tests of Clinical Chemistry, Hematology, and Urinalysis. The investigator determined if the result was potentially clinically significant.</description>
        <time_frame>Baseline (Day 1) to Week 4</time_frame>
        <population>Safety Population included of all participants who received ≥ 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Potentially Clinically Significant Change in Laboratory Tests</title>
          <description>Laboratory tests included tests of Clinical Chemistry, Hematology, and Urinalysis. The investigator determined if the result was potentially clinically significant.</description>
          <population>Safety Population included of all participants who received ≥ 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced Potentially Clinically Significant Change in Vital Signs</title>
        <description>Vital signs assessments included: pulse, respiratory rate, and blood pressure (systolic and diastolic). The investigator determined if the result was potentially clinically significant.</description>
        <time_frame>Baseline (Day 1) to Week 4</time_frame>
        <population>Safety Population included of all participants who received ≥ 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Potentially Clinically Significant Change in Vital Signs</title>
          <description>Vital signs assessments included: pulse, respiratory rate, and blood pressure (systolic and diastolic). The investigator determined if the result was potentially clinically significant.</description>
          <population>Safety Population included of all participants who received ≥ 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced Clinically Significant Change From Baseline in General Physical Condition as Measured Through General Physical Exam</title>
        <description>General Physical Examination consisted of a full review of body systems excluding pelvic and rectal exams. The investigator determined if the result was clinically significant.</description>
        <time_frame>Baseline (Day 1) to Week 4</time_frame>
        <population>Safety Population included of all participants who received ≥ 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Clinically Significant Change From Baseline in General Physical Condition as Measured Through General Physical Exam</title>
          <description>General Physical Examination consisted of a full review of body systems excluding pelvic and rectal exams. The investigator determined if the result was clinically significant.</description>
          <population>Safety Population included of all participants who received ≥ 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 4-week Average of Daily Bowel Movement Frequency During the Treatment Period</title>
        <description>Bowel movements were recorded by the participant in an electronic diary (e-diary). The number of bowel movements per day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1) to Week 4</time_frame>
        <population>mITT Population included of all participants in enrolled population with ≥ 1 postbaseline assessment for BSFS.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 4-week Average of Daily Bowel Movement Frequency During the Treatment Period</title>
          <description>Bowel movements were recorded by the participant in an electronic diary (e-diary). The number of bowel movements per day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
          <population>mITT Population included of all participants in enrolled population with ≥ 1 postbaseline assessment for BSFS.</population>
          <units>bowel movements per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" spread="2.792"/>
                    <measurement group_id="O2" value="2.86" spread="1.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="1.509"/>
                    <measurement group_id="O2" value="-0.79" spread="0.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 4-week Average of Daily Worst Abdominal Pain Scores During the Treatment Period</title>
        <description>The participant recorded their worst abdominal pain score in the past 24 hours each day in an e-diary where: 0=no pain to 10=worst imaginable pain. The score each day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1) to Week 4</time_frame>
        <population>mITT Population included of all participants in enrolled population with ≥ 1 postbaseline assessment for BSFS.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 4-week Average of Daily Worst Abdominal Pain Scores During the Treatment Period</title>
          <description>The participant recorded their worst abdominal pain score in the past 24 hours each day in an e-diary where: 0=no pain to 10=worst imaginable pain. The score each day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
          <population>mITT Population included of all participants in enrolled population with ≥ 1 postbaseline assessment for BSFS.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="1.510"/>
                    <measurement group_id="O2" value="3.13" spread="1.755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.769"/>
                    <measurement group_id="O2" value="-1.28" spread="1.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 4-week Average of Daily Bloating Scores During the Treatment Period</title>
        <description>The participant recorded their bloating score in the past 24 hours each day in an e-diary where: 0=no bloating to 10=worst imaginable bloating. The score each day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1) to Week 4</time_frame>
        <population>mITT Population included of all participants in enrolled population with ≥ 1 postbaseline assessment for BSFS.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 4-week Average of Daily Bloating Scores During the Treatment Period</title>
          <description>The participant recorded their bloating score in the past 24 hours each day in an e-diary where: 0=no bloating to 10=worst imaginable bloating. The score each day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
          <population>mITT Population included of all participants in enrolled population with ≥ 1 postbaseline assessment for BSFS.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="2.291"/>
                    <measurement group_id="O2" value="4.07" spread="2.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="1.572"/>
                    <measurement group_id="O2" value="-1.46" spread="1.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 4-week Average Number of Daily Urgent Bowel Movements During the Treatment Period</title>
        <description>The participant recorded the number of urgent bowel movements in the past 24 hours each day in an e-diary. The number of urgent bowel movements per day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1) to Week 4</time_frame>
        <population>mITT Population included of all participants in enrolled population with ≥ 1 postbaseline assessment for BSFS.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 4-week Average Number of Daily Urgent Bowel Movements During the Treatment Period</title>
          <description>The participant recorded the number of urgent bowel movements in the past 24 hours each day in an e-diary. The number of urgent bowel movements per day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
          <population>mITT Population included of all participants in enrolled population with ≥ 1 postbaseline assessment for BSFS.</population>
          <units>urgent bowel movements per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.179"/>
                    <measurement group_id="O2" value="1.22" spread="0.652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.736"/>
                    <measurement group_id="O2" value="-0.80" spread="0.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Fecal Incontinence During the Treatment Period</title>
        <description>The participant recorded the number of fecal incontinences in the past 24 hours each day in an e-diary. Fecal incontinence is the inability to control the passage of gas or stools. The number of fecal incontinences per day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1) to Week 4</time_frame>
        <population>mITT Population included of all participants in enrolled population with ≥ 1 postbaseline assessment for BSFS.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Fecal Incontinence During the Treatment Period</title>
          <description>The participant recorded the number of fecal incontinences in the past 24 hours each day in an e-diary. Fecal incontinence is the inability to control the passage of gas or stools. The number of fecal incontinences per day was averaged over the 4-week period. A negative change from Baseline indicates improvement.</description>
          <population>mITT Population included of all participants in enrolled population with ≥ 1 postbaseline assessment for BSFS.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Irritable Bowel Syndrome Quality of Life (IBS-QOL) Total Score at the End of the Treatment Period</title>
        <description>IBS-QOL is composed of 34 items about how the symptoms of IBS are impacting the participant's life scored on a 1 to 5 scale, where lower item scores indicate greater quality of life. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0 to 100-point scale (0=worst; 100=better) for ease of interpretation. A positive change from Baseline indicates improved quality of life.</description>
        <time_frame>Baseline (Day1) to End of Treatment (Up to Week 4)</time_frame>
        <population>mITT Population included of all participants in enrolled population with ≥ 1 postbaseline assessment for BSFS.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Irritable Bowel Syndrome Quality of Life (IBS-QOL) Total Score at the End of the Treatment Period</title>
          <description>IBS-QOL is composed of 34 items about how the symptoms of IBS are impacting the participant's life scored on a 1 to 5 scale, where lower item scores indicate greater quality of life. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0 to 100-point scale (0=worst; 100=better) for ease of interpretation. A positive change from Baseline indicates improved quality of life.</description>
          <population>mITT Population included of all participants in enrolled population with ≥ 1 postbaseline assessment for BSFS.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="14.43"/>
                    <measurement group_id="O2" value="71.4" spread="13.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="11.70"/>
                    <measurement group_id="O2" value="13.2" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Serum 7α-hydroxy-4-cholesten-3-one (7αC4) Levels at the End of the Treatment Period</title>
        <description>Participants fasted for at least 8 hours prior to the test. Fasting serum 7αC4 level was measured at Baseline and End of Treatment to determine whether any changes occurred following treatment with eluxadoline. The negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1) to End of Treatment (Up to Week 4)</time_frame>
        <population>mITT Population included of all participants in enrolled population with ≥ 1 postbaseline assessment for BSFS. Number analyzed is the number of participants with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Serum 7α-hydroxy-4-cholesten-3-one (7αC4) Levels at the End of the Treatment Period</title>
          <description>Participants fasted for at least 8 hours prior to the test. Fasting serum 7αC4 level was measured at Baseline and End of Treatment to determine whether any changes occurred following treatment with eluxadoline. The negative change from Baseline indicates improvement.</description>
          <population>mITT Population included of all participants in enrolled population with ≥ 1 postbaseline assessment for BSFS. Number analyzed is the number of participants with data available for analyses.</population>
          <units>nanogram/milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.95" spread="27.259"/>
                    <measurement group_id="O2" value="30.58" spread="17.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at End of Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.59" spread="32.841"/>
                    <measurement group_id="O2" value="-8.78" spread="12.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Concentration for Eluxadoline</title>
        <time_frame>Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2</time_frame>
        <population>Pharmacokinetic (PK) population included all participants in the enrolled population and whose dry blood sample (DBS) was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Concentration for Eluxadoline</title>
          <population>Pharmacokinetic (PK) population included all participants in the enrolled population and whose dry blood sample (DBS) was collected.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="1.34"/>
                    <measurement group_id="O2" value="0.91" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmin: Minimum Concentration for Eluxadoline</title>
        <time_frame>Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2</time_frame>
        <population>PK population included all participants in the enrolled population and whose DBS was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin: Minimum Concentration for Eluxadoline</title>
          <population>PK population included all participants in the enrolled population and whose DBS was collected.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.44"/>
                    <measurement group_id="O2" value="0.42" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC: Area Under the Concentration-time Curve During the Dosing Interval for Eluxadoline</title>
        <time_frame>Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2</time_frame>
        <population>PK population included all participants in the enrolled population and whose DBS was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC: Area Under the Concentration-time Curve During the Dosing Interval for Eluxadoline</title>
          <population>PK population included all participants in the enrolled population and whose DBS was collected.</population>
          <units>nanogram* hour/milliliter (ng*h/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.22" spread="8.46"/>
                    <measurement group_id="O2" value="7.75" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Cmax for Eluxadoline</title>
        <time_frame>Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2</time_frame>
        <population>PK population included all participants in the enrolled population and whose DBS was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Cmax for Eluxadoline</title>
          <population>PK population included all participants in the enrolled population and whose DBS was collected.</population>
          <units>hours (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="2.5"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2: Half-Life for Eluxadoline</title>
        <time_frame>Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2</time_frame>
        <population>PK population included all participants in the enrolled population and whose DBS was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2: Half-Life for Eluxadoline</title>
          <population>PK population included all participants in the enrolled population and whose DBS was collected.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" lower_limit="24.7" upper_limit="58.1"/>
                    <measurement group_id="O2" value="35.2" lower_limit="24.7" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F: Apparent Total Clearance of the Drug From Plasma After Oral Administration for Eluxadoline</title>
        <time_frame>Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2</time_frame>
        <population>PK population included all participants in the enrolled population and whose DBS was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F: Apparent Total Clearance of the Drug From Plasma After Oral Administration for Eluxadoline</title>
          <population>PK population included all participants in the enrolled population and whose DBS was collected.</population>
          <units>liter/hour (L/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20236" spread="13280"/>
                    <measurement group_id="O2" value="21901" spread="11921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vc/F: Apparent Volume of Distribution for Eluxadoline</title>
        <time_frame>Predose and at the intervals 1-2, 3-4 and 5-8 hours postdose at Week 2</time_frame>
        <population>PK population included all participants in the enrolled population and whose DBS was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 100 mg With BAM</title>
            <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg Without BAM</title>
            <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Vc/F: Apparent Volume of Distribution for Eluxadoline</title>
          <population>PK population included all participants in the enrolled population and whose DBS was collected.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29432" spread="11000"/>
                    <measurement group_id="O2" value="39799" spread="10637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eluxadoline 100 mg With BAM</title>
          <description>IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Eluxadoline 100 mg Without BAM</title>
          <description>IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA: 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyschezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired fasting glucose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>IR-CTRegistration@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

